Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara
about
Smallpox vaccines for biodefense: need and feasibilitySmallpox vaccine: the good, the bad, and the ugly.Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverA pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizationsInduction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesVaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo.Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene.Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in miceSelection of recombinant MVA by rescue of the essential D4R gene.Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications.CD8 T cells are essential for recovery from a respiratory vaccinia virus infection.Reflections on the early development of poxvirus vectors.Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancerSmallpox vaccines for biodefense.Defending against smallpox: a focus on vaccines.Influence of glycosylation and oligomerization of vaccinia virus complement control protein on level and pattern of functional activity and immunogenicity.Generation of transduction-competent retroviral vectors by infection with a single hybrid vaccinia virus.Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice.Effect of NF-kappaB constitutive activation on proliferation and apoptosis of gastric cancer cell lines.Challenges and Achievements in Prevention and Treatment of Smallpox.
P2860
Q22305942-F9C9B037-C93A-435A-93E4-E5CC26477B0DQ24520563-ADD7AFD5-2334-4B4A-86EC-DF2DCF0FABCBQ28740522-84A587EC-FC94-4688-A870-25A623A74F50Q28749671-2D2FD2B2-C054-4730-ABFF-EF5FC84CF5D2Q30339052-E4C7DB9D-9DCF-4DC0-AF7F-3C57F6667D68Q30375489-F4ABDCC3-D923-4D70-AE48-F5532783062EQ33401609-2B86AB1C-2D2E-4F4A-A1C7-88BB72514782Q33440600-1F17547E-285D-4B38-A291-A02F9B873510Q33838507-B9A8D496-2734-47FD-BED6-82F48711B6ADQ33932404-1EE69153-37F3-4BAA-ABF9-21451F0E0986Q34471962-47B2A0DA-3F9F-49F4-B970-45C980F3A360Q34651266-88E3B455-37BB-4335-BFD3-505181977967Q34907430-9FB6D9F2-6C60-4518-AAC7-B18E08F1DE69Q35202797-63951B58-7C35-48C5-96D5-BD92804DFE85Q35800430-22736D3D-5E61-40F0-AFF3-C3734A534E39Q35826728-40B5CB83-3230-425B-9BE3-8F22B4BD503EQ36394928-31BF439C-3028-430B-A9DC-049DF4A59AEBQ37126266-0ECA7377-7BDA-4E9F-8D49-31623BA03D18Q37389574-6C56F15C-9CDC-4521-9EEA-32967E10D48AQ37393765-38CF6030-3E07-462F-B335-650E0385DEE5Q38799357-8034CF06-2557-46F5-8690-59FEF5AC55B7Q39611097-74D2C0C9-D3A8-48DF-A4A0-E7BBF11335B4Q39650382-8888481A-A18A-4723-A892-5C01DD27656AQ39864202-1E80082D-D9F5-46AA-AEB3-10EDC36DCCC4Q40419711-7748C63D-6BD6-43B6-A438-EF8444A8CD84Q47547852-B4451312-AC35-46C8-9F37-EA27EC096FA2
P2860
Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@ast
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@en
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@nl
type
label
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@ast
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@en
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@nl
prefLabel
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@ast
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@en
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@nl
P2093
P2860
P1433
P1476
Immunogenicity and safety of d ...... modified vaccinia virus Ankara
@en
P2093
F G Falkner
H Savidis-Dacho
M Gerencer
S Coulibaly
W Gritschenberger
P2860
P304
P356
10.1128/JVI.76.15.7713-7723.2002
P407
P577
2002-08-01T00:00:00Z